Study of Oral MRT-2359 in Selected Cancer Patients
NSCLC · SCLC · High Grade Neuroendocrine Cancer · DLBCL · L-MYC and N-MYC Amplified Solid Tumors · NSCLC With High or Low L-MYC or N-MYC Expression · HR-positive, HER2-negative Breast Cancer · Prostate Cancer
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +10
Pushed back a key date by about 7 months
Since Nov 6, 2026 · was worth 10, fading over time
- +2.7
2 insiders sold shares within a month
Since Jul 16, 2026 · was worth 10, fading over time
Score over time
- Stage
- Phase 1/2
- Patients
- 174 (planned)
- Started
- Oct 12, 2022
- Main results expected
- Dec 2026
- Fully finished
- Nov 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Phase 1 Evaluates safety and tolerability of MRT-2359 over a 28-day cycle by the occurrence and frequency of dose limiting toxicities (DLTs) for determination of the MTD and/or RP2D
Measured over: 28 days
Phase 2 Evaluates preliminary anti-tumor activity of MRT-2359 by overall response rate (ORR) as determined by RECIST 1.1
Measured over: 56 days (up to approximately 24 months from screening to end of study participation
Changes Tremor has spotted
Pushed back the main results date by about 7 months: May 2026 → Dec 2026.
The company is Monte Rosa Therapeutics, which trades as GLUE, and it is testing an oral cancer drug called MRT-2359 in a Phase 1/2 trial (an early-stage study that checks safety and looks for signs the drug works). The trial has stopped signing up new patients but is still running, and the date for its main results has moved from May 2026 to December 2026, about 7 months later. Investors watch for this kind of change because a delayed results date can hint that the study is taking longer than planned, which might point to slower enrollment, extra follow-up, or problems in the data. Still, a date moving is also common for ordinary reasons, such as scheduling changes or a decision to collect more information, so by itself it doesn't show that anything is wrong with the drug or the study.
AI-written from the facts above
Spotted
Show details (technical version)
Score inputs
- date_delayed: base 10, now 10, since 2026-11-06, fades (half-life)
- insider_selling_cluster: base 10, now 2.7, since 2026-07-16, fades (half-life)
Raw record changes
- 2026-11-06 15:29 UTC · date_delayed · primary_completion_date
old: "2026-05"
new: "2026-12"
details: {"months":7}
Trial ID NCT05546268 · record last updated 2026-11-06 · checked 2026-11-09 06:30 UTC